Brief exposure of embryos to steroids or aromatase inhibitor induces sex reversal in Nile tilapia (Oreochromis niloticus).
This study aimed to develop sex reversal procedures targeting the embryonic period as tools to study the early steps of sex differentiation in Nile tilapia with XX, XY, and YY sexual genotypes. XX eggs were exposed to masculinizing treatments with androgens (17α-methyltestosterone, 11-ketotestosterone) or aromatase inhibitor (Fadrozole), whereas XY and YY eggs were subjected to feminizing treatments with estrogen analog (17α-ethynylestradiol). All treatments consisted of a single or double 4-hr immersion applied between 1 and 36 hour post-fertilization (hpf). Concentrations of active substances were 1000 or 2000 μg l(-1) in XX and XY, and 2000 or 6500 μg l(-1) in YY. Masculinizing treatments of XX embryos achieved a maximal sex reversal rate of 10% with an exposure at 24 hpf to 1000 μg l(-1) of 11-ketotestosterone or to 2000 μg l(-1) of Fadrozole. Feminization of XY embryos was more efficient and induced up to 91% sex reversal with an exposure to 2000 μg l(-1) of 17α-ethynylestradiol. Interestingly, similar treatments failed to reverse YY fish to females, suggesting either that a sex determinant linked to the Y chromosome prevents the female pathway when present in two copies, or that a gene present on the X chromosome is needed for the development of a female phenotype.
Aquaculture Research and Education Center (CEFRA), AFFISH-RC, University of Liè, ge, Tihange, Belgium.
Vincent
V
Gennotte
Patrick
P
Mafwila Kinkela
Bernard
B
Ulysse
Dieudonné
D
Akian Djétouan
Frédéric
F
Bere Sompagnimdi
Thomas
T
Tomson
Charles
C
Mélard
Carole
C
Rougeot
D000818:Animals; D047072:Aromatase Inhibitors / Q000494:pharmacology; D023681:Cichlids / Q000196:embryology / Q000235:genetics / Q000502:physiology*; D012734:Disorders of Sex Development; D004965:Estrogen Antagonists / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000494:pharmacology; D017316:Fadrozole / Q000494:pharmacology; D005260:Female; D008297:Male; D008777:Methyltestosterone / Q000494:pharmacology; D012733:Sex Differentiation / Q000187:drug effects*; D013256:Steroids; D013739:Testosterone / Q000031:analogs & derivatives / Q000494:pharmacology
D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D013256:Steroids; D013739:Testosterone; D004997:Ethinyl Estradiol; D017316:Fadrozole; C003600:11-ketotestosterone; D008777:Methyltestosterone